Related Experiment Video

Updated: Jun 27, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

ErbB antagonists patenting: "playing chess with cancer"

Sami Aifa1, Ahmed Rebai

  • 1Unit of Bioinformatics and Signalling, Centre of Biotechnology of Sfax, P.O. Box 1177, Sidi Mansour Road 3018, Sfax, Tunisia. sami.aifa@cbs.rnrt.tn

Recent Patents on Biotechnology
|December 17, 2008
PubMed

Insights

Targeting ErbB receptors with monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) shows promise in cancer treatment. However, drug resistance necessitates combination therapies for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) signaling pathways are crucial in solid tumor development.
  • Dysregulated ErbB signaling drives cell cycle progression (MAPK pathway) and survival (PI3K pathway) in many cancers.

Purpose of the Study:

  • To review the development and clinical application of ErbB antagonists, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs).
  • To discuss the mechanisms of resistance encountered with current ErbB-targeted therapies.
  • To highlight the emerging strategy of combination therapies for overcoming treatment resistance.

Main Methods:

  • Review of patented monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) targeting ErbB receptors.
  • Analysis of clinical applications and resistance mechanisms associated with approved anti-ErbB drugs.
  • Exploration of future therapeutic strategies involving combination treatments.

Main Results:

  • Approved mAbs (Trastuzumab, Cetuximab, Panitumumab) and TKIs (Gefitinib, Erlotinib, Lapatinib) target EGFR and/or HER2.
  • Resistance to mAbs occurs via compensatory signaling, while TKI resistance arises from mutations in the tyrosine kinase domain.
  • Drug resistance significantly limits the efficacy of current monotherapies.

Conclusions:

  • Monoclonal antibodies and tyrosine kinase inhibitors targeting ErbB signaling are vital in cancer treatment.
  • Mechanisms of resistance, including compensatory signaling and target mutations, pose significant challenges.
  • Combination therapy represents a promising future strategy to overcome resistance and improve cancer treatment efficacy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...